DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. (DRIO) on September 16, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
On September 16, 2024, the Company received notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2). The Company's closing bid price for its common stock remained below $1.00 per share for 30 consecutive business days.
- Compliance Period: The Company has been granted an initial 180-calendar day period to regain compliance, ending March 17, 2025.
- Requirement: To regain compliance, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days within the compliance period.
- Trading Status: The common stock will continue to be listed and traded on Nasdaq during this period.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and consider available options to resolve the non-compliance. The filing explicitly states there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or other listing criteria.
If the Company fails to comply by March 17, 2025, it may be afforded a second 180-day compliance period, provided it meets the market value of publicly held shares requirement and other initial listing standards. Failure to regain compliance within all allotted periods will result in a notice of delisting.
Key Facts for Investor Verification
- Verify the current closing bid price of DRIO common stock relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of trading above $1.00 before the March 17, 2025 deadline.
- Review the Company's market value of publicly held shares to assess eligibility for a potential second compliance period.
- Check for any subsequent filings regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.